CD 1599
Alternative Names: CD-1599Latest Information Update: 10 Jan 2008
Price :
$50 *
At a glance
- Originator Galderma
- Class Antiacnes; Antineoplastics
- Mechanism of Action Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acne; Leukaemia
Most Recent Events
- 06 Jun 2001 No-Development-Reported for Acne in USA (unspecified route)
- 06 Jun 2001 No-Development-Reported for Leukaemia in USA (unspecified route)
- 23 Sep 1998 Preclinical development for Acne in USA (unspecified route)